Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Evotec, Bionamics GmbH Acquisition to accelerate “EVT Innovate” strategy

Published: Monday, March 24, 2014
Last Updated: Monday, March 24, 2014
Bookmark and Share
The acquisition expands discovery pipeline with portfolio of projects especially in Multiple Sclerosis and CNS.

Evotec AG today announced the acquisition of the Germany-based Bionamics GmbH. Bionamics is an asset management company that focuses on the translation of academic innovations into attractive assets for the biotech and Pharma industry. The transaction comprises the acquisition of all shares of Bionamics against cash and future milestone payments. Next to an experienced management team Bionamics brings a portfolio of highly attractive and fully funded projects especially in neurodegeneration and CNS to Evotec.
 
Further financial details of the transaction remain undisclosed.
 
Dr Werner Lanthaler, Chief Executive Officer of Evotec, said: “With the acquisition of Bionamics we accelerate our EVT Innovate strategy and enlarge our reach towards outstanding innovations. We welcome the openness of Bionamics to join the discovery infrastructure of Evotec. We are also very happy to welcome Dr Timm Jessen back at Evotec. In his new management role, Dr Jessen will be responsible for the commercialisation of “EVT Innovate” projects.”
 
Dr Timm Jessen, Managing Director of Bionamics GmbH, commented: “We highly value Evotec’s strategic appreciation of our work and its success as demonstrated e.g. in managing the NEU² programme, a consortium of academic, biotech and Pharma partners focussing on novel products to treat Multiple Sclerosis and other neurodegenerative diseases. The combination of our management skills with Evotec’s strong operational capabilities offers a unique constellation for researchers and entrepreneurs around the globe to accelerate their innovation together with us. I very much look forward to expand this concept further within the Evotec Group.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Evotec Achieves Clinical Development Milestone from Bayer
Company announces milestone achieved for the progression of a programme from the alliance portfolio into Phase I clinical development for the treatment of endometriosis, triggering a milestone payment to Evotec.
Thursday, August 04, 2016
Evotec Extends Integrated Drug Discovery Alliance With Genentech
Evotec and Genentech will continue their drug discovery alliance for a further three years.
Tuesday, May 24, 2016
Evotec Awarded Contract to Manage NCI CBC Screening Libraries Center
Company will provide compound management services for a period of five years.
Friday, October 09, 2015
Evotec, Apeiron Biologics and Sanofi Collaborate
Evotec AG and Apeiron Biologics AG, a biotech company with a focus on immunological approaches to treat cancer, have announced a strategic collaboration with Sanofi to develop novel small molecule-based cancer immunotherapies.
Monday, August 10, 2015
Evotec & Facio Partner
Facio partners with Evotec and initiates FSHD drug discovery programme.
Friday, May 08, 2015
Evotec and Padlock Therapeutics Extend Collaboration
Evotec and Padlock Therapeutics announce initial success and extension of long-term collaboration.
Friday, January 09, 2015
Evotec and Sanofi Enter into Exclusive Negotiations
Goal to improve innovation effectiveness in drug discovery and pre-clinical development.
Thursday, December 04, 2014
Evotec And The Jain Foundation Expand Collaboration
The collaboration marks the start of multiple drug screening programmes.
Monday, September 15, 2014
Evotec, Medicines for Malaria Announce Compound Management Collaboration
The collaboration will support MMV’s Malaria and Pathogen Box initiatives.
Tuesday, August 19, 2014
Evotec Receives First Milestone in Roche Biomarker Collaboration
Evotec AG announce the successful achievement of a milestone in its biomarker alliance with Roche.
Thursday, April 24, 2014
Evotec Enters Integrated Alliance with AstraZeneca
Initial focus of the alliance will be exploring compounds and targets with novel mechanisms that have disease-modifying potential for the treatment of chronic kidney disease.
Monday, October 21, 2013
Evotec and Harvard Stem Cell Institute form CureMN Collaboration to Advance ALS Research
Strategic partnership established with the Harvard Stem Cell Institute (“HSCI”) to identify compounds that prevent or slow down the loss of motor neurons.
Thursday, September 12, 2013
Evotec and Dow AgroSciences Collaborate on Cellular Target Profiling
Collaboration has objective of leveraging Evotec’s advanced chemical proteomics services to support compounds in development at Dow AgroSciences.
Tuesday, July 09, 2013
Evotec AG: New Hormone to Treat Diabetes Published in “Cell”
Harvard University Prof. Doug Melton and his post doc Peng Yi describe the new hormone “betatrophin” that controls beta cell proliferation as potential diabetes treatment.
Friday, April 26, 2013
Evotec Achieves Milestone in Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd.
Evotec receives a milestone payment from Ono for the progression of a compound into pre-clinical development.
Friday, January 11, 2013
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Identified Compound Stops Cells Making Ribosomes
From study in yeast, researchers have identifed a compound that interferes with the assembly of ribosomes.
CES Score May Predict Response to Cancer Treatment
Researchers identify new type of biomarker that helps predict prognosis and response to several types of cancer treatment.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
New Therapeutic Target for Crohn’s Disease
A promising new target for drugs that treat IBD has been identified along with a possible biomarker for IBD severity.
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
Researchers Find Fungus-Fighting Compound
A compound has been identifed that blocks growth of a fungus responsible for lung infections and allergic reactions.
Peer Reviewed Study Demonstrates Mass Spec Technique
The peer reviewed study demonstrates MS workflow, TMTCalibrator workflow, which dramatically enhances detection of key early stage Alzheimer’s biomarkers.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!